- L-Nutra secured $36.5M in a strategic investment from Mubadala as part of its Series D round, bringing the round total to $83.5M.
- The funding supports major global expansion, alongside plans to launch a joint venture in Abu Dhabi to produce medical nutrition therapies and longevity-focused nutrition for the MENA region.
- The deal reflects Mubadala’s growing focus on longevity, backed by its ~$330B portfolio and previous investments in companies like Juvena Therapeutics, Juvenescence, and Rejuveron.
Nutri-technology company L-Nutra has secured an additional $36.5 million in its Series D funding round through a strategic investment from Mubadala Investment Company, supporting the company’s science-backed nutrition programs designed to promote healthier living and longevity.
The latest investment brings the total amount raised in the round to $83.5 million, paving the way for major international growth. The two organizations also revealed plans to establish a joint venture in Abu Dhabi, focused on producing medical nutrition therapies and longevity-centered nutrition solutions tailored for the Middle East and North Africa (MENA) region.
Abu Dhabi-based sovereign investor Mubadala manages a global portfolio of approximately $330 billion across multiple sectors, with a growing interest in longevity. In recent years, Mubadala has backed several longevity-focused companies including Juvena Therapeutics, Juvenescence, and Rejuveron.
“This investment reinforces Abu Dhabi’s ambition to expand as a regional hub for longevity science, preventive health, and advanced nutrition technologies,” said Ismail Ali Abdulla of Mubadala, describing the move as a natural extension of the UAE’s emerging life sciences ecosystem.
